Arcadia Biosciences (RKDA) 10-Q 7 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 26, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	RKDA
Entity Registrant Name	ARCADIA BIOSCIENCES, INC.
Entity Central Index Key	1,469,443
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		4,774,919
Entity Emerging Growth Company	true
Entity Small Business	true
Extended Transition Period	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,669	$ 9,125
Short-term investments	17,931	3,898
Accounts receivable	193	1,231
Unbilled revenue	168	4
Inventories — current	354	229
Prepaid expenses and other current assets	888	560
Total current assets	26,203	15,047
Property and equipment, net	265	299
Inventories — noncurrent	742	1,168
Other noncurrent assets	7	56
Total assets	27,217	16,570
Current liabilities:
Accounts payable and accrued expenses	2,303	2,496
Amounts due to related parties	18	29
Unearned revenue — current	316	1,000
Total current liabilities	2,637	3,525
Unearned revenue — noncurrent		2,038
Common stock warrant liabilities	8,658
Other noncurrent liabilities	3,000	3,000
Total liabilities	14,295	8,563
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 4,774,919 and 2,134,154 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	45	42
Additional paid-in capital	190,599	175,223
Accumulated deficit	(177,720)	(167,257)
Accumulated other comprehensive loss	(2)	(1)
Total stockholders’ equity	12,922	8,007
Total liabilities and stockholders’ equity	$ 27,217	$ 16,570

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	4,774,919	2,134,154
Common stock, outstanding	4,774,919	2,134,154

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 370	$ 589	$ 1,020	$ 2,598
Operating expenses:
Research and development	1,334	1,749	4,524	5,241
Selling, general and administrative	3,011	2,415	8,581	8,410
Total operating expenses	4,469	4,204	13,536	13,913
Loss from operations	(4,099)	(3,615)	(12,516)	(11,315)
Interest expense		(43)		(747)
Other income, net	134	46	266	246
Initial loss on common stock warrant and common stock adjustment feature liability			(4,000)
Change in fair value of common stock warrant liabilities and common stock adjustment feature liability	8,421		5,986
Offering costs	(1)		(2,544)
Loss on extinguishing of debt		(900)		(900)
Net income (loss) before income taxes	4,455	(4,512)	(12,808)	(12,716)
Income tax provision	(5)	(13)	(26)	(31)
Net income (loss)	$ 4,450	$ (4,525)	$ (12,834)	$ (12,747)
Net income (loss) per share attributable to common stockholders:
Basic and diluted	$ 0.93	$ (2.12)	$ (3.74)	$ (5.89)
Weighted-average number of shares used in per share calculations:
Basic and diluted	4,774,732	2,133,846	3,427,799	2,163,604
Other comprehensive income (loss), net of tax
Unrealized losses (gains) on available-for-sale securities	$ (2)	$ 8	$ (1)	$ 14
Other comprehensive loss (income)	(2)	8	(1)	14
Comprehensive income (loss) attributable to common stockholders	4,448	(4,517)	(12,835)	(12,733)
Product
Revenues:
Total revenues	144	82	393	482
Operating expenses:
Cost of product revenues	124	40	431	262
License
Revenues:
Total revenues	10	144	100	353
Contract Research And Government Grants
Revenues:
Total revenues	$ 216	$ 363	$ 527	$ 1,763

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	June Offering [Member]	June Purchase Agreement [Member]	Common Stock [Member]	Common Stock [Member]Securities Purchase Agreement [Member]	Common Stock [Member]June Purchase Agreement [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]June Offering [Member]	Additional Paid-In Capital [Member]Securities Purchase Agreement [Member]	Additional Paid-In Capital [Member]June Purchase Agreement [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2016	$ 22,198			$ 44			$ 173,723				$ (151,550)	$ (19)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2016				2,224,384
Issuance of shares related to employee stock purchase plan	24						24
Issuance of shares related to employee stock purchase plan, Shares				1,964
Stock-based compensation	1,474						1,474
Other comprehensive loss (income)	18											18
Exchange of membership interest in unconsolidated entity for common stock				$ (2)			2
Exchange of membership interest in unconsolidated entity for common stock, Shares				(92,194)
Net loss	(15,707)										(15,707)
Stockholders Equity, Ending Balance at Dec. 31, 2017	8,007			$ 42			175,223				(167,257)	(1)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2017				2,134,153
Impact of adoption of Topic 606 (Note 5) | Topic 606 [Member]	2,371										2,371
Issuance of shares related to employee stock option exercises	$ 963						963
Issuance of shares related to employee stock option exercises, Shares	44,354			44,354
Issuance of shares related to employee stock purchase plan	$ 6						6
Issuance of shares related to employee stock purchase plan, Shares				1,122
Issuance of shares			$ 4,978		$ 1	$ 2			$ (1)	$ 4,976
Issuance of shares, Shares					1,201,634	1,392,345
Issuance of placement agent warrants	526	$ 427					526	$ 427
Reclassification of common stock adjustment feature liability balance	8,378						8,378
Offering costs related to June Offering			$ (897)							$ (897)
Stock-based compensation	998						998
Issuance of shares related to reverse stock split, Shares				1,311
Other comprehensive loss (income)	(1)											(1)
Net loss	(12,834)										(12,834)
Stockholders Equity, Ending Balance at Sep. 30, 2018	$ 12,922			$ 45			$ 190,599				$ (177,720)	$ (2)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2018				4,774,919

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,834)	$ (12,747)
Adjustments to reconcile net loss to cash used in operating activities:
Initial loss on common stock warrant and common stock adjustment feature liabilities	4,000
Change in fair value of common stock warrant liabilities and common stock adjustment feature liability	(5,986)
Offering costs	2,544
Depreciation and amortization	123	215
Gain on disposal of equipment	(3)	(3)
Net amortization of investment premium	(115)	(82)
Stock-based compensation	998	1,177
Loss on sale of investments		2
Accretion of debt discount		98
Loss on extinguishment of debt		900
Changes in operating assets and liabilities:
Accounts receivable	1,038	276
Unbilled revenue	(164)	123
Inventories	301	164
Prepaid expenses and other current assets	(334)	(222)
Other noncurrent assets		(245)
Accounts payable and accrued expenses	(142)	(496)
Amounts due to related parties	(11)	1
Unearned revenue	(351)	(443)
Net cash used in operating activities	(10,936)	(11,282)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	10	4
Purchases of property and equipment	(89)	(77)
Purchases of investments	(22,871)	(19,405)
Proceeds from sales and maturities of investments	8,950	57,778
Net cash (used in) provided by investing activities	(14,000)	38,300
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Purchase Agreement	10,000
Payments of offering costs relating to Purchase Agreement	(1,308)
Proceeds from issuance of common stock and warrants from June Offering	14,000
Payments of offering costs relating to June Offering	(1,181)
Payment of debt extinguishment costs		(1,125)
Proceeds from exercise of stock options and ESPP purchases	969	24
Payment on notes payable		(25,000)
Net cash provided by (used in) financing activities	22,480	(26,101)
Net (decrease) increase in cash and cash equivalents	(2,456)	917
Cash and cash equivalents — beginning of period	9,125	2,013
Cash and cash equivalents — end of period	6,669	2,930
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest		746
Cash paid for income taxes	24	2
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs related to Purchase Agreement	526
Common stock warrants issued to placement agent and included in offering costs related to June Offering	239
Purchases of property and equipment included in accounts payable and accrued expenses		2
Reclassification of common stock adjustment feature liability balance to equity	$ 8,378
Exchange of membership interest in unconsolidated entity for common stock		$ 2

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. We are a consumer-driven, agricultural food ingredient company. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed high value crop productivity traits designed to enhance farm economics. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , Common Stock Authorized In June 2017, the shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to reduce the number of authorized common stock from four hundred million to one hundred and fifty million shares. Reverse Stock Split In January 2018, the Company’s board of directors and its shareholders approved a reverse split of 1:20 on the Company’s issued and outstanding common stock which became effective on January 23, 2018. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. The reverse stock split did not change the total number of authorized shares of common stock which remained at one hundred and fifty million shares. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and Verdeca in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities (“VIEs”). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Interim results are not necessarily indicative of results for any other interim period or for the full fiscal year. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2018. Liquidity and Capital Resources As of September 30, 2018, the Company had an accumulated deficit of $177.7 million, cash and cash equivalents of $6.7 million and short-term investments of $17.9 million. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to research and development activities, including the discovery, advancement, and testing of the Company’s traits and products incorporating the Company’s traits. To date, we have not generated revenues from sales of commercial products, other than limited revenues from the Company’s SONOVA products. In March 2018, the Company executed securities purchase agreements with institutional investors in connection with a private placement of common stock and warrants in the amount of $10.0 million, exclusive of any related transaction fees, which funding improved the Company’s liquidity position. In June 2018, the Company executed agreements with institutional investors for the purchase of common stock and warrants in the amount of $14.0 million, exclusive of related transaction fees, further improving the Company’s liquidity position. With cash and cash equivalents of $6.7 million and short-term investments of $17.9 million as of September 30, 2018, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of 12 months from the issuance of these condensed consolidated financial statements. The Company may seek to raise additional funds through debt or equity financings, if necessary. The Company may also consider entering into additional partner arrangements or pursuing additional government grants. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the company does require additional funds and are not able to secure adequate additional funding, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2018
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, Revenue from Contracts with Customers (Topic 606) In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Codification Improvements to Topic 842, Leases Leases (Topic 824) – Targeted Improvements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments — Overall (Subtopic 825-10) The Company is currently evaluating the impact of the adoption of ASU No. 2018-03 on its condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement The Company is currently evaluating the impact of the adoption of ASU No. 2018-13 on its condensed consolidated financial statements.

SONOVA Gamma Linolenic Acid ("G

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory	3. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory Raw materials costs consist primarily of seed production costs incurred by the Company’s contracted cooperators. Finished goods inventories consist of GLA oil that is available for sale. The Company recorded a $46,000 write-down of inventory for the three months ended September 30, 2018 and $223,000 for the nine months ended September 30, 2018. The Company did not record an inventory write-down for the three and nine months ended September 30, 2017. Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 45 $ 45 Finished goods 1,051 1,352 Inventories $ 1,096 $ 1,397

Investments and Fair Value of F

Investments and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2018
Investments And Fair Value Of Financial Instruments [Abstract]
Investments and Fair Value of Financial Instruments	4. Investments and Fair Value of Financial Instruments Available-for-Sale Investments The Company classified short-term investments as “available-for-sale.” These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss, which is reflected as a separate component of stockholder’s equity in the Consolidated Balance Sheets. Gains and losses are recognized when realized in the Consolidated Statements of Operations and Comprehensive Loss. The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at September 30, 2018 and December 31, 2017, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value September 30, 2018 Cash equivalents: Money market funds 6,325 — — 6,325 Short-term investments: Treasury Bills 11,163 — (2 ) 11,161 U.S. government securities 2,797 — — 2,797 Commercial paper 3,973 — — 3,973 Total Assets at Fair Value $ 24,258 $ — $ (2 ) $ 24,256 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2017 Cash equivalents: Money market funds $ 8,943 $ — $ — $ 8,943 Short-term investments: Commercial paper 1,399 — — 1,399 U.S. government securities 2,500 — (1 ) 2,499 Total Assets at Fair Value $ 12,842 $ — $ (1 ) $ 12,841 The Company did not have any investment categories that were in a continuous unrealized loss position for more than three months as of September 30, 2018. The unrealized gains and losses amounts above are included in accumulated other comprehensive income or loss. As of September 30, 2018, for fixed income securities that were in unrealized loss positions, the Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such fixed income securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three and nine months ended September 30, 2018. Fair Value Measurement Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable, approximated their fair values due to the short period of time to maturity or repayment. The following table sets forth the fair value of the Company’s financial assets and liabilities as of September 30, 2018 and December 31, 2017: Fair Value Measurements at September 30, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,325 $ — $ — $ 6,325 Short-term investments: Treasury Bills 11,161 — — 11,161 U.S. government securities 2,797 — — 2,797 Commercial paper — 3,973 — 3,973 Total Assets at Fair Value $ 20,283 $ 3,973 $ — $ 24,256 Liabilities at Fair Value Common stock warrant liabilities $ — $ — $ 8,658 $ 8,658 Total Liabilities at Fair Value $ — $ — $ 8,658 $ 8,658 Fair Value Measurements at December 31, 2017 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 8,943 $ — $ — $ 8,943 Short-term investments: Commercial paper — 1,399 — 1,399 U.S. government securities 2,499 — — 2,499 Total Assets at Fair Value $ 11,442 $ 1,399 $ — $ 12,841 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2018 or 2017. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, short-term investments and accounts payable and accrued liabilities. For accounts receivable, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2018 and December 31, 2017 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities, which were measured and recorded on a recurring basis, consist of liabilities related to the Purchase Agreement and the June Offering described in Note 9. The following table sets forth the establishment of these liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - Purchase Agreement Common Stock Adjustment Feature Liability - Purchase Agreement Common Stock Warrant Liability - June Offering Total Balance as of December 31, 2017 $ — $ — $ — $ — Common stock and warrants issued in conjunction with securities purchase agreements 10,200 3,800 9,022 23,022 Change in fair value and other adjustments (6,192 ) 4,578 (4,372 ) (5,986 ) Reclassification of common stock adjustment feature liability balance to equity — (8,378 ) — (8,378 ) Balance as of September 30, 2018 $ 4,008 $ — $ 4,650 $ 8,658 In determining the fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below: • Money market funds, treasury bills, and U.S. government securities – Investments in money market funds, treasury bills, and U.S. government securities are classified within Level 1. At September 30, 2018 and December 31, 2017, these investments were included on the consolidated balance sheets in cash and cash equivalents and short-term investments. • Commercial paper – Investments in commercial paper are classified within Level 2. At September 30, 2018 and December 31, 2017, commercial paper investments were included on the consolidated balance sheets in short-term investments. • Purchase Agreement common stock warrant liability – The Company has outstanding warrants to purchase 1,282,832 shares of common stock that it issued to certain accredited investors and its placement agent on March 22, 2018 (as described in Note 9). The common stock warrants were classified as a liability within Level 3 based on the instrument’s adjustment features and a contingent cash payment feature . The Company utilized a binomial-lattice pricing model (the Monte Carlo simulation model) that involves a market condition to estimate the fair value of the common stock warrants. The application of the Monte Carlo simulation model requires the use of several assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrant. Although the terms of the common stock warrants became known and fixed following the May 7, 2018 shareholder meeting, the common stock warrants remained a liability given the contingent cash payment feature was still present. The estimated fair value of the common stock warrant liability was subsequently remeasured at September 30, 2018 utilizing a Black Scholes Merton model with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss. • Purchase Agreement common stock adjustment feature liability – The Company issued 1,201,634 shares of common stock to certain accredited investors following the closing of the Private Placement on March 22, 2018 (as described in Note 9). The number of common stock shares issued, along with the number and exercise price of the common stock warrants issued, was subject to price adjustments. This common stock adjustment feature was initially classified as a liability within Level 3 based on the instruments adjustment features . The Company utilizes a binomial-lattice pricing model (the Monte Carlo simulation model) that involves a market condition to estimate the fair value of this feature. The application of the Monte Carlo simulation model requires the use of several assumptions including the Company’s stock price, expected life of the feature, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and risk-free interest rate for the expected life of the common stock adjustment feature. The estimated fair value of the common stock adjustment feature was subsequently remeasured at March 31, 2018 and at May 7, 2018 with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss. The liability balance at May 7, 2018 was reclassified to equity as the number of common stock shares issuable became known and fixed. • June Offering common stock warrant liability – The Company has outstanding warrants to purchase 1,461,962 shares of common stock that it issued to certain accredited investors on June 14, 2018 (as described in Note 9). The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature . The initial estimated fair value of the common stock warrant liability was subsequently remeasured at September 30, 2018 with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss.

Adoption of ASC Topic 606 "Reve

Adoption of ASC Topic 606 "Revenue from Contracts with Customers"	9 Months Ended
	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Adoption of ASC Topic 606, Revenue from Contracts with Customers	5. Adoption of ASC Topic 606, “Revenue from Contracts with Customers” In May 2014, the FASB issued ASU No. 2014-09 (Topic 606) "Revenue from Contracts with Customers." Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605) and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented in accordance with Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historical accounting under Topic 605. With the adoption of Topic 606, tax recognition will now follow book recognition for up-front license and commercial value sharing fees. Annual license fees and milestone fees may continue to be recognized differently for book and tax to the extent that revenue recognized for book is prior to cash receipts. The Company recorded a net reduction to its accumulated deficit of $2.4 million on January 1, 2018, with a corresponding reduction to unearned revenue, due to the cumulative impact of adopting Topic 606. The adjustment pertained to up-front license fees which were previously deferred for which the performance obligation was determined to be complete as of the date of adoption. The impact to revenues with the adoption of Topic 606 for the three and nine months ended September 30, 2018 was a decrease of $82,000 and $246,000, respectively, relating to the above mentioned up-front license fee revenues. Revenues represent amounts earned from product sales, grants and contract research and license agreements. As it pertains to product sales and grants and contract research, there are no changes from Topic 605 compared to the adoption of Topic 606. There is a change in methodology from Topic 605 to Topic 606 that impacts the recognition of revenues from license agreements. The Company’s license agreements have one performance obligation and various payment terms over a long commercial development timeline ranging from approximately 10 to 20 years. These payment terms may contain, but are not limited to: 1. Up-front non-refundable license fees 2. Annual license fees 3. Milestone fees 4. Commercial value share fees Under Topic 605, up-front license fees were deferred and amortized over the estimated commercial development timeline. Under Topic 606, such fees will be recognized upon execution of the agreement. The deferred balance remaining from the existing portfolio of license agreements that were executed prior to January 1, 2018 were recorded as a reduction to accumulated deficit upon the adoption of ASC 606 on January 1, 2018. Up-front license fees for newly executed agreements will be recognized upon execution. Under Topic 605, annual license fees were recognized on the annual due date as such fees were not due if a milestone was met or if termination of the agreement occurred. Under Topic 606, a nnual license fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Under Topic 605, milestone fees were recognized when the Company and partner licensee mutually agreed the milestone had been achieved. Under Topic 606, milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones are probable in order to determine the timing of revenue recognition for milestone fees. There is no change from Topic 605 to Topic 606 pertaining to future commercial value revenue recognition. Commercial value share fees will be recognized based on subsequent sales by the licensee.

Variable Interest Entity

Variable Interest Entity	9 Months Ended
	Sep. 30, 2018
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	6. Variable Interest Entity In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. The Company determined that a de facto agency relationship between the Company and Bioceres exists. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. Both the Company and Bioceres incur expenses in support of specific activities, as agreed upon by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amounts of $286,000, $ 261,000 487,000

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	7. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Dow AgroSciences, LLC (“Dow”) and involves a joint operating activity where both Arcadia and Dow are active participants in the activities of the collaboration. Arcadia and Dow participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Dow will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	8. Debt Long-term Debt There was no long-term debt as of September 30, 2018 and December 31, 2017. Term Loan In December 2015, the Company entered into a loan and security agreement (“Term Loan”) with Silicon Valley Bank (the “Bank”) providing for a senior secured term loan facility in the amount of $25.0 million, which proceeds were used to repay all existing debt. In July 2017, the Company repaid the T erm Loan with Silicon Valley Bank, along with the $625,000 end-of-term fee and $500,000 prepayment fee. The Company recognized interest expense of $43,000 and $747,000 for the three and nine months ended September 30, 2017, respectively, of which $0 and $98,000 was related to the debt discount, respectively. There was no interest expense recognized for the three and nine months ended September 30, 2018.

Private Placement and Register

Private Placement and Registered Direct Offering	9 Months Ended
	Sep. 30, 2018
Warrants And Rights Note Disclosure [Abstract]
Private Placement and Registered Direct Offering Disclosure	9. Private Placement and Registered Direct Offering Private Placement On March 22, 2018, the Company issued 300,752 shares of its common stock (“Common Stock”) and warrants to purchase up to 300,752 shares of Common Stock with an initial exercise price equal to $45.75 (the “Warrants”), in a private placement (the “Private Placement”) in accordance with a securities purchase agreement (the “Purchase Agreement”) entered into with certain institutional and accredited investors (collectively, the “Purchasers”) on March 19, 2018. The Warrants are immediately exercisable, subject to certain ownership limitations, and expire five years after the date of issuance. The per share purchase price of the Common Stock and per share exercise price for the Warrants were subject to adjustment based on the volume weighted average price for the three trading days (the “VWAP Calculation”) after each of the following: (i) the date that a registration statement covering the resale of the securities being issued in the Private Placement (“Resale Registration Statement”) has been declared effective by the SEC, (ii) if a registration statement covering all securities issued in the Private Placement is not declared effective, then the date that the securities can be sold under Rule 144 under the Securities Act of 1933, as amended, and (iii) if later than the dates set forth in item (i) and (ii), then the date that the Company’s shareholders approve the Private Placement. After each adjustment, the per share purchase price for Common Stock was automatically reduced to 80% of the VWAP Calculation, and the per share exercise price for the Warrant was automatically reduced, to 110% of the VWAP Calculation; provided, that in no event, will the per share purchase price for the Common Stock or the exercise price for the Warrants be less than $8.322. Upon any adjustment of the per share exercise price for the Warrants, then the number of shares exercisable under the Warrants shall be increased so that the aggregate exercise price payable after adjustment is equal to the aggregate exercise price payable prior to such adjustment. The Company filed the Resale Registration Statement with the SEC on March 30, 2018, and it was declared effective on April 23, 2018. As described above and based upon the applicable VWAP Calculations relating to these events, each of these events caused an adjustment to the number of shares issued in the Private Placement and underlying the Warrants. Following the effectiveness of the Resale Registration Statement, on April 23, 2018 the number of shares issued pursuant to the Purchase Agreement increased from 300,752 to 798,754, the total number of shares issuable upon exercise of the Warrants increased from 300,752 to 799,300 and the per share exercise price of the Warrants reduced from $45.75 to $17.2143. The Company held a special meeting of its shareholders on May 2, 2018 and obtained shareholder approval for the issuance of Common Stock in the Private Placement. Following shareholder approval of the issuance of shares in the Private Placement, on May 8, 2018 the number of shares issued pursuant to the Purchase Agreement increased from 798,754 to 1,201,636, the total number of shares issuable upon exercise of the Warrants increased from 799,300 to 1,282,832 and the per share exercise price of the Warrants reduced from $17.2143 to $10.7258. These condensed consolidated financial statements reflect these additional issuances. The aggregate net proceeds received by the Company from the Private Placement was $8.7 million, consisting of gross proceeds of $10.0 million less offering costs of $1.3 million. The Company entered into the Private Placement to secure additional capital to strengthen its cash resources required to launch its new health and nutrition ingredient product commercialization and production scale-up plans, as well as to continue the deregulation and commercialization of its stress tolerant HB4 soybean trait. More specifically, net proceeds will be used for working capital to fund the continued introgression of quality ingredient traits into elite germ plasm, additional seed bulk-up, increased planting acreage, consumer brand development and a number of other pre-commercialization and commercialization activities. The common stock adjustment feature and common stock warrants were determined to be liabilities based on each instrument’s adjustment features and the contingent cash payment feature of the common stock warrants. The liabilities were accounted for at their respective fair values at inception using a Monte Carlo simulation model with the following assumptions: volatility of 100 percent, stock price of $32.52 and risk-free rate of 2.63%. At inception, the fair values of the common stock adjustment feature and the common stock warrant liabilities were $3.8 million and $10.2 million, respectively. As the combined value of the liabilities exceeded the $10.0 million of proceeds, no value was assigned to the common stock issued and an initial loss of $4.0 million was recognized. The liabilities are marked-to-market and were valued at $15.9 million at March 31, 2018, resulting in an additional loss of $1.9 million in the first quarter of 2018. In May 2018, following the Private Placement’s final adjustment, the terms of the warrants and the number of common stock shares issuable in the private placement became known and fixed. As a result, the common stock adjustment feature liability was marked-to-market and valued at $8.4 million at May 7, 2018, resulting in an additional loss of $2.4 million recognized in the second quarter of 2018. The Company subsequently reclassified the common stock adjustment feature liability’s balance of $8.4 million to stockholders’ equity. The common stock warrant liability was marked-to-market and valued at $8.0 million at June 30, 2018, resulting in income of $1.9 million recognized in the second quarter of 2018. The common stock warrant liability was marked-to-market and valued at $4.0 million at September 30, 2018, resulting in income of $4.0 million recognized in the third quarter of 2018. The common stock warrant liability remained at September 30, 2018 as the contingent cash payment feature was still in effect. Registration Rights Agreement In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company filed the Resale Registration Statement with the SEC on March 30, 2018 for purposes of registering the resale of the shares of Common Stock issued pursuant to the Purchase Agreement and the shares of Common Stock issuable upon exercise of the Warrants. The SEC declared the registration statement effective on April 23, 2018. Offering Costs In connection with the Private Placement, the Company paid to a placement agent an aggregate fee equal to $850,000. The Company also granted warrants to purchase a total of 15,038 shares of common stock (the “Placement Agent Warrants”) that have an exercise price per share equal to $41.5625 and a term of five years. The Placement Agent Warrants were issued for services performed by the placement agent as part of the Private Placement and were treated as offering costs. The value of the Placement Agent Warrants was determined to be $526,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $458,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the Private Placement. The offering costs, inclusive of the Placement Agent Warrants, totaled $1.8 million, of which $0 and $1.8 million were expensed in the three and nine months ended September 30, 2018, respectively. Registered Direct Offering On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018. This shelf registration process allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having an aggregate initial offering price of $50 million. On June 11, 2018, the Company entered into agreements with several institutional and accredited investors (the “June Purchase Agreement”) for the purchase of 1,392,345 shares of its common stock at a purchase price of $9.93 per share for gross proceeds of $13.8 million (the “June Offering”). The 1,392,345 shares of common stock sold in the June Offering were issued pursuant to a prospectus, dated June 8, 2018, and a prospectus supplement dated June 11, 2018, in connection with a takedown from the Company’s shelf Registration Statement on Form S-3. The June Offering closed on June 14, 2018. Additionally, in a concurrent private placement (the “June Private Placement”), the Company issued to the investors unregistered warrants to purchase up to 1,392,345 shares of common stock at a purchase price per warrant of $0.125, for gross proceeds of $174,000. The warrants, and the shares of common stock underlying the warrants, have not been registered with the SEC and have an exercise price of $9.94 per share. Subject to certain ownership limitations, the warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The aggregate net proceeds received by the Company for the June Offering were $12.8 million, consisting of gross proceeds of $14.0 million less offering costs of $1.2 million. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, scale-up of its GoodWheat TM The common stock warrants were determined to be a liability as they have a contingent cash payment feature. The common stock warrants were accounted for at their fair value at inception using a Black Scholes Merton model with the following assumptions: volatility of 108 percent, stock price of $8.20 and risk-free rate of $2.83%. At inception, the fair value of the common stock warrants was $9.0 million and the remaining $5.0 million of the $14.0 million of proceeds was allocated to the common stock using the residual method and accounted for as stockholders’ equity. The common stock warrants were marked-to-market and valued at $9.1 million at June 30, 2018, resulting in a loss of $42,000 in the second quarter of 2018. The common stock warrants were marked-to-market and valued at $4.6 million at September 30, 2018, resulting in income of $4.5 million recognized in the third quarter of 2018. Offering Costs In connection with the June Offering, the Company paid to a placement agent an aggregate fee equal to $980,000. The Company also granted warrants to purchase a total of 69,617 shares of common stock (“June Placement Agent Warrants”) that have an exercise price per share equal to $12.568 and a term of five years. The Placement Agent Warrants were issued for services performed by the placement agent as part of the June Offering and were treated as offering costs. The value of the June Placement Agent Warrants was determined to be $427,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $197,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the June Offering. The offering costs, inclusive of the June Placement Agent Warrants, totaled $1.6 million and allocated to the common stock warrant liability and the common stock using their relative fair values. A total of $710,000 was allocated to the common stock warrant liability, of which $4,000 and $710,000 were expensed in the three and nine months ended September 30, 2018. The remaining $897,000 was allocated to the common stock and offset to additional paid in capital.

Stock-Based Compensation and Wa

Stock-Based Compensation and Warrants	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]
Stock-Based Compensation and Warrants	10. Stock-Based Compensation and Warrants Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when the 2006 Plan was terminated as to future awards. The 2006 Plan continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter; however, the options granted in the third quarter of 2018 vest over a two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years after grant. As of September 30, 2018, a total of 484,539 shares of common stock were reserved for issuance under the 2015 Plan, of which 26,740 shares of common stock are available for future grant. As of September 30, 2018, a total of 67,397 and 457,797 options are outstanding under the 2006 and 2015 Plans, respectively. A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2017 288,129 $ 63.62 $ — Options granted 287,577 6.76 Options exercised (44,354 ) 21.73 Options cancelled and forfeited (6,158 ) 41.54 Outstanding — Balance at September 30, 2018 525,194 $ 36.34 $ 63 Vested and expected to vest — September 30, 2018 510,184 $ 36.90 $ 61 Exercisable —September 30, 2018 149,624 $ 84.00 $ 1 As of September 30, 2018, there was $1.7 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.2 years. The fair value of stock option awards to executives and employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected term (years) 5.52 6.00 5.97 6.12 Expected volatility 100% 80% 99% 79% Risk-free interest rate 2.96% 1.94% 2.95% 1.89% Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September 30, 2018, the number of shares of common stock reserved for future issuance under the ESPP is 89,489. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2018, 6,853 shares had been issued under the ESPP. The Company recorded $4,000 and $ 6,000 Warrants As of September 2018, the Company has 2,826,687 common stock warrants outstanding with a weighted average exercise price of $18.78. The expiration of the warrants range from December 2018 to June 2023. On December 2013, the Company issued warrants to Mahyco International to purchase 3,784 shares of common stock, exercisable as of the issuance date, at an exercise price of $330.40 per share. The warrants expire five years from the issuance date. In connection with the Series D preferred stock financing in the first half of 2014, the Company issued warrants, exercisable as of the issuance date, to the Series D preferred stock investors to purchase an aggregate of 61,397 shares of common stock at an exercise price of $363.20 per share and to the placement agents to purchase 1,674 shares of common stock at $268.80. The warrants expire five years from the issuance date. As of September 2018, 1,282,832 common stock warrants are outstanding that were issued in the June Private Placement. The final exercise price for these warrants is $10.7258 as adjusted in accordance with the Purchase Agreement’s adjustment provisions. See Note 9. As of September 2018, 1,461,962 common stock warrants are outstanding in accordance with the June Offering. Of the total, 1,392,345 shares have a purchase price of $9.94 and the remaining 69,617 common stock warrants have an exercise price of $12.568. See Note 9.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes expense is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company’s effective tax rate (ETR) was 0.1% and -0.2% for the three and nine months ended September 30, 2018 and -0.2% for the three and nine months ended September 30, 2017. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets and foreign withholding taxes. The Company may have experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the Purchase Agreement in March 2018 or in the June Offering. Such an ownership change may limit the Company’s ability to utilize its net operating loss carryforwards prior to expiration. Given the full valuation allowance, such a limitation would not impact the deferred tax asset balance as currently recorded. As of September 30, 2018, there have been no material changes to the Company’s uncertain tax positions.

Contingent Liability Related to

Contingent Liability Related to the Anawah Acquisition	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Contingent Liability Related to the Anawah Acquisition	12. Contingent Liability Related to the Anawah Acquisition On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs, thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. As of September 30, 2018, the Company continues to pursue three development programs using this technology and believes that the contingent liability is probable. As a result, $3.0 million remains on the Condensed Consolidated Balance Sheet as an other noncurrent liability.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss per Share	13. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As of September 30, 2018, all potentially dilutive common shares were determined to be anti-dilutive after evaluation. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Nine Months Ended September 30, 2018 2017 Options to purchase common stock 525,194 293,288 Warrants to purchase common stock 2,826,687 66,845 Total 3,351,881 360,133

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related-Party Transactions	14. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Revocable Trust (“JSRV”). The rights to the intellectual property previously owned by Blue Horse Labs, Inc. (“BHL”) were assigned to JSRV due to BHL’s dissolution. The JSRV is deemed a related party of the Company because MCC, the Company’s largest stockholder, and JSRV share some common officers and directors. Transactions with related parties are reflected in the condensed consolidated financial statements under amounts due to related parties. JSRV receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSRV, and previously BHL, were $18,000 and $29,000 as of September 30, 2018 and December 31, 2017, respectively, and are included in the Condensed Consolidated Balance Sheets as amounts due to related parties.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events The Company has reviewed and evaluated subsequent events through November 7, 2018, the date the condensed consolidated financial statements were available to be issued.

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. We are a consumer-driven, agricultural food ingredient company. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed high value crop productivity traits designed to enhance farm economics. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca ,
Common Stock Authorized	Common Stock Authorized In June 2017, the shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to reduce the number of authorized common stock from four hundred million to one hundred and fifty million shares.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and Verdeca in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities (“VIEs”). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Interim results are not necessarily indicative of results for any other interim period or for the full fiscal year. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2018.
Liquidity and Capital Resources	Liquidity and Capital Resources As of September 30, 2018, the Company had an accumulated deficit of $177.7 million, cash and cash equivalents of $6.7 million and short-term investments of $17.9 million. Since the Company’s inception, substantially all of the Company’s efforts have been devoted to research and development activities, including the discovery, advancement, and testing of the Company’s traits and products incorporating the Company’s traits. To date, we have not generated revenues from sales of commercial products, other than limited revenues from the Company’s SONOVA products. In March 2018, the Company executed securities purchase agreements with institutional investors in connection with a private placement of common stock and warrants in the amount of $10.0 million, exclusive of any related transaction fees, which funding improved the Company’s liquidity position. In June 2018, the Company executed agreements with institutional investors for the purchase of common stock and warrants in the amount of $14.0 million, exclusive of related transaction fees, further improving the Company’s liquidity position. With cash and cash equivalents of $6.7 million and short-term investments of $17.9 million as of September 30, 2018, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of 12 months from the issuance of these condensed consolidated financial statements. The Company may seek to raise additional funds through debt or equity financings, if necessary. The Company may also consider entering into additional partner arrangements or pursuing additional government grants. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the company does require additional funds and are not able to secure adequate additional funding, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

SONOVA Gamma Linolenic Acid (_2

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 45 $ 45 Finished goods 1,051 1,352 Inventories $ 1,096 $ 1,397

Investments and Fair Value of_2

Investments and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Investments And Fair Value Of Financial Instruments [Abstract]
Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at September 30, 2018 and December 31, 2017, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value September 30, 2018 Cash equivalents: Money market funds 6,325 — — 6,325 Short-term investments: Treasury Bills 11,163 — (2 ) 11,161 U.S. government securities 2,797 — — 2,797 Commercial paper 3,973 — — 3,973 Total Assets at Fair Value $ 24,258 $ — $ (2 ) $ 24,256 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2017 Cash equivalents: Money market funds $ 8,943 $ — $ — $ 8,943 Short-term investments: Commercial paper 1,399 — — 1,399 U.S. government securities 2,500 — (1 ) 2,499 Total Assets at Fair Value $ 12,842 $ — $ (1 ) $ 12,841
Summary of Fair Value of Financial Assets and Liabilities	The following table sets forth the fair value of the Company’s financial assets and liabilities as of September 30, 2018 and December 31, 2017: Fair Value Measurements at September 30, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,325 $ — $ — $ 6,325 Short-term investments: Treasury Bills 11,161 — — 11,161 U.S. government securities 2,797 — — 2,797 Commercial paper — 3,973 — 3,973 Total Assets at Fair Value $ 20,283 $ 3,973 $ — $ 24,256 Liabilities at Fair Value Common stock warrant liabilities $ — $ — $ 8,658 $ 8,658 Total Liabilities at Fair Value $ — $ — $ 8,658 $ 8,658 Fair Value Measurements at December 31, 2017 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 8,943 $ — $ — $ 8,943 Short-term investments: Commercial paper — 1,399 — 1,399 U.S. government securities 2,499 — — 2,499 Total Assets at Fair Value $ 11,442 $ 1,399 $ — $ 12,841
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of these liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - Purchase Agreement Common Stock Adjustment Feature Liability - Purchase Agreement Common Stock Warrant Liability - June Offering Total Balance as of December 31, 2017 $ — $ — $ — $ — Common stock and warrants issued in conjunction with securities purchase agreements 10,200 3,800 9,022 23,022 Change in fair value and other adjustments (6,192 ) 4,578 (4,372 ) (5,986 ) Reclassification of common stock adjustment feature liability balance to equity — (8,378 ) — (8,378 ) Balance as of September 30, 2018 $ 4,008 $ — $ 4,650 $ 8,658

Stock-Based Compensation and _2

Stock-Based Compensation and Warrants (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2017 288,129 $ 63.62 $ — Options granted 287,577 6.76 Options exercised (44,354 ) 21.73 Options cancelled and forfeited (6,158 ) 41.54 Outstanding — Balance at September 30, 2018 525,194 $ 36.34 $ 63 Vested and expected to vest — September 30, 2018 510,184 $ 36.90 $ 61 Exercisable —September 30, 2018 149,624 $ 84.00 $ 1
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards to executives and employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected term (years) 5.52 6.00 5.97 6.12 Expected volatility 100% 80% 99% 79% Risk-free interest rate 2.96% 1.94% 2.95% 1.89%

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Nine Months Ended September 30, 2018 2017 Options to purchase common stock 525,194 293,288 Warrants to purchase common stock 2,826,687 66,845 Total 3,351,881 360,133

Description of Business and B_3

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	May 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Place of incorporation			Arizona
Year of incorporation			2,002
Place of reincorporation			Delaware
Date of reincorporation			2015-03
Common stock, authorized						150,000,000	400,000,000
Reverse split of issued and outstanding common stock			1:20
Accumulated deficit			$ (177,720)	$ (167,257)
Cash and cash equivalents			6,669	9,125	$ 2,930			$ 2,013
Short-term investments			17,931	$ 3,898
Proceeds from issuance of private placement	$ 14,000	$ 10,000	$ 10,000

SONOVA Gamma Linolenic Acid (_3

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventory written down	$ 46,000	$ 0	$ 223,000	$ 0

SONOVA Gamma Linolenic Acid (_4

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 45	$ 45
Finished goods	1,051	1,352
Inventories	$ 1,096	$ 1,397

Investments and Fair Value of_3

Investments and Fair Value of Financial Instruments - Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 24,258	$ 12,842
Unrealized Gains	0	0
Unrealized Losses	(2)	(1)
Estimated Fair Value	24,256	12,841
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,325	8,943
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	6,325	8,943
Short-term Investments [Member] | Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	11,163
Unrealized Gains	0
Unrealized Losses	(2)
Estimated Fair Value	11,161
Short-term Investments [Member] | U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,797	2,500
Unrealized Gains	0	0
Unrealized Losses	0	(1)
Estimated Fair Value	2,797	2,499
Short-term Investments [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,973	1,399
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	$ 3,973	$ 1,399

Investments and Fair Value of_4

Investments and Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Mar. 22, 2018	Sep. 30, 2018	Jun. 14, 2018
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Investment in continuous unrealized loss position for more than three months		$ 0
Securities Purchase Agreement [Member] | Private Placement [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued	300,752
Common Stock Warrant Liability [Member] | Securities Purchase Agreement [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued	1,282,832
Common Stock Warrant Liability [Member] | Securities Purchase Agreement [Member] | Level 3 [Member] | June Offering [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued			1,461,962
Common Stock Adjustment Feature Liability [Member] | Securities Purchase Agreement [Member] | Level 3 [Member] | Private Placement [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued	1,201,634

Investments and Fair Value of_5

Investments and Fair Value of Financial Instruments - Summary of Fair Value of Financial Assets and Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets at Fair Value
Total Assets at Fair Value	$ 24,256	$ 12,841
Liabilities at Fair Value
Total Liabilities at Fair Value	8,658
Common Stock Warrant Liability [Member]
Liabilities at Fair Value
Total Liabilities at Fair Value	8,658
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	20,283	11,442
Liabilities at Fair Value
Total Liabilities at Fair Value	0
Level 1 [Member] | Common Stock Warrant Liability [Member]
Liabilities at Fair Value
Total Liabilities at Fair Value	0
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	3,973	1,399
Liabilities at Fair Value
Total Liabilities at Fair Value	0
Level 2 [Member] | Common Stock Warrant Liability [Member]
Liabilities at Fair Value
Total Liabilities at Fair Value	0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Liabilities at Fair Value
Total Liabilities at Fair Value	8,658
Level 3 [Member] | Common Stock Warrant Liability [Member]
Liabilities at Fair Value
Total Liabilities at Fair Value	8,658
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	6,325	8,943
Money Market Funds [Member] | Level 1 [Member]
Assets at Fair Value
Cash equivalents	6,325	8,943
Money Market Funds [Member] | Level 2 [Member]
Assets at Fair Value
Cash equivalents	0	0
Money Market Funds [Member] | Level 3 [Member]
Assets at Fair Value
Cash equivalents	0	0
Treasury Bills [Member]
Assets at Fair Value
Short-term investments	11,161
Treasury Bills [Member] | Level 1 [Member]
Assets at Fair Value
Short-term investments	11,161
Treasury Bills [Member] | Level 2 [Member]
Assets at Fair Value
Short-term investments	0
Treasury Bills [Member] | Level 3 [Member]
Assets at Fair Value
Short-term investments	0
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	2,797	2,499
U.S. Government Securities [Member] | Level 1 [Member]
Assets at Fair Value
Short-term investments	2,797	2,499
U.S. Government Securities [Member] | Level 2 [Member]
Assets at Fair Value
Short-term investments	0	0
U.S. Government Securities [Member] | Level 3 [Member]
Assets at Fair Value
Short-term investments	0	0
Commercial Paper [Member]
Assets at Fair Value
Short-term investments	3,973	1,399
Commercial Paper [Member] | Level 1 [Member]
Assets at Fair Value
Short-term investments	0	0
Commercial Paper [Member] | Level 2 [Member]
Assets at Fair Value
Short-term investments	3,973	1,399
Commercial Paper [Member] | Level 3 [Member]
Assets at Fair Value
Short-term investments	$ 0	$ 0

Investments and Fair Value of_6

Investments and Fair Value of Financial Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock and warrants issued in conjunction with securities purchase agreements	$ 23,022
Change in fair value and other adjustments	(5,986)
Reclassification of common stock adjustment feature liability balance to equity	(8,378)
Balance as of September 30, 2018	8,658
Common Stock Warrant Liability [Member] | Private Placement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock and warrants issued in conjunction with securities purchase agreements	10,200
Change in fair value and other adjustments	(6,192)
Balance as of September 30, 2018	4,008
Common Stock Warrant Liability [Member] | June Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock and warrants issued in conjunction with securities purchase agreements	9,022
Change in fair value and other adjustments	(4,372)
Balance as of September 30, 2018	4,650
Common Stock Adjustment Feature Liability [Member] | Private Placement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock and warrants issued in conjunction with securities purchase agreements	3,800
Change in fair value and other adjustments	4,578
Reclassification of common stock adjustment feature liability balance to equity	$ (8,378)

Adoption of ASC Topic 606, "Rev

Adoption of ASC Topic 606, "Revenue from Contracts with Customers" - Additional Information (Detail) - Topic 606 [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Impact of adoption of Topic 606 (Note 5)		$ 2,371,000
Impact to revenues	$ (82,000)	$ (246,000)
Revenue From License Agreement [Member] | Minimum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	10 years	10 years
Revenue From License Agreement [Member] | Maximum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	20 years	20 years

Variable Interest Entity - Addi

Variable Interest Entity - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2012Owner	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Variable Interest Entity [Line Items]
Direct expenses and allocated overhead amount | $		$ 286,000	$ 261,000	$ 799,000	$ 487,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of shareholders owning agricultural investment and development cooperative | Owner	300

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Debt - Long Term Debt - Additio

Debt - Long Term Debt - Additional Information (Detail) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Long term debt	$ 0	$ 0

Debt - Term Loan - Additional I

Debt - Term Loan - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ (900,000)		$ (900,000)
Repayment of accrued interest and prepayment fee			43,000		747,000
Accretion of debt discount					98,000
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 25,000,000
Debt instrument end-of-term fee	$ 625,000
Debt instrument prepayment fee	$ 500,000
Loss on extinguishment of debt				$ (1,100,000)
Deferred loan issuance fees		$ 41,000		41,000
Partially offset end of term fee previously amortized				267,000
Partially offset end of term fee previously amortized netting				(900,000)
Repayment of accrued interest and prepayment fee		$ 0	43,000	$ 0	747,000
Accretion of debt discount			$ 0		$ 98,000

Private Placement and Registere

Private Placement and Registered Direct Offering - Additional Information (Detail)	Jun. 11, 2018USD ($)$ / sharesshares	May 11, 2018USD ($)$ / sharesshares	May 08, 2018$ / sharesshares	Apr. 23, 2018$ / sharesshares	Mar. 22, 2018$ / sharesshares	Mar. 19, 2018	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	May 07, 2018USD ($)	Dec. 31, 2013$ / shares
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares									$ 18.78			$ 18.78		$ 330.40
Period of trading days taken for calculation of volume weighted average price												3 days
Percentage of volume weighted average price of common stock												80.00%
Percentage of volume weighted average price of warrant												110.00%
Proceeds from issuance of private placement							$ 14,000,000	$ 10,000,000				$ 10,000,000
Offering costs									$ 197,000			$ 197,000
Stock price | $ / shares									$ 32.52			$ 32.52
Fair value of liabilities									$ 8,658,000			$ 8,658,000
Common stock no par value | $ / shares
Initial loss recognized on liabilities												$ 4,000,000
Liabilities marked to market value								$ 15,900,000			$ 15,900,000
Additional income (loss) on liabilities											$ (1,900,000)
Offering cost, expense									$ 1,000			2,544,000
Issuance of placement agent warrants												526,000
Proceeds from issuance initial public offering												50,000,000
Fair value of common stock warrants at inception									$ 9,000,000			9,000,000
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance of placement agent warrants												$ 526,000
Placement Agent [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares									15,038			15,038
Warrants issued, exercise price | $ / shares									$ 41.5625			$ 41.5625
Offering costs									$ 1,800,000			$ 1,800,000
Warrant, exercisable term												5 years
Offering cost, expense									$ 0			$ 1,800,000
June Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares									69,617			69,617
Warrants issued, exercise price | $ / shares									$ 12.568			$ 12.568
Offering costs									$ 1,600,000			$ 1,600,000
Aggregate agent fee paid												$ 980,000
Warrant, exercisable term												5 years
Offering cost, expense									4,000			$ 710,000
Issuance of placement agent warrants												427,000
Offering costs portion attributable to common stock									$ 897,000			$ 897,000
Measurement Input, Price Volatility [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate									1			1
Measurement Input, Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate									0.0263			0.0263
Black Scholes Merton model [Member]
Class Of Warrant Or Right [Line Items]
Stock price | $ / shares									$ 8.20			$ 8.20
Black Scholes Merton model [Member] | Measurement Input, Price Volatility [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate									1.08			1.08
Black Scholes Merton model [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate									0.0283			0.0283
Common Stock Adjustment Feature Liability [Member] | Monte Carlo Simulation Model [Member]
Class Of Warrant Or Right [Line Items]
Fair value of liabilities									$ 3,800,000			$ 3,800,000
Common Stock Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Fair value of liabilities									8,658,000			8,658,000
Liabilities marked to market value									4,600,000			4,600,000
Additional income (loss) on liabilities									4,500,000
Proceeds from issuance of common stock												5,000,000
Proceeds from issuance of common stock and warrants gross												14,000,000
Common Stock Warrant Liability [Member] | Monte Carlo Simulation Model [Member]
Class Of Warrant Or Right [Line Items]
Fair value of liabilities									$ 10,200,000			$ 10,200,000
Minimum [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares									$ 8.322			$ 8.322
Purchase price of common stock | $ / shares									8.322			8.322
June Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares									$ 10.7258			$ 10.7258
Offering costs									$ 1,200,000			$ 1,200,000
Proceeds from issuance of common stock and warrants gross												14,000,000
Proceeds from issuance of common stock and warrants net												12,800,000
June Purchase Agreement [Member] | Common Stock Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value							9,100,000			$ 9,100,000
Additional income (loss) on liabilities										(42,000)
Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance of private placement												8,700,000
Proceeds from offering costs of private placement, gross												10,000,000
Offering costs									1,300,000			1,300,000
Liabilities marked to market value													$ 8,400,000
Additional income (loss) on liabilities										(2,400,000)
Reclassification of financing liabilities to stockholders equity							8,400,000			8,400,000
Private Placement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs									458,000			458,000
Private Placement [Member] | Placement Agent [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid												850,000
Private Placement [Member] | Common Stock Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value							$ 8,000,000		4,000,000	8,000,000		4,000,000
Additional income (loss) on liabilities									$ 4,000,000	$ 1,900,000
Private Placement [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares					300,752
Warrant issued, shares of common stock called by warrant | shares					300,752
Warrants issued, exercise price | $ / shares					$ 45.75
Warrants expiration period						5 years
Applicable VWAP CalculationsI in Accordance with Registration [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares				798,754
Warrant issued, shares of common stock called by warrant | shares				799,300
Warrants issued, exercise price | $ / shares				$ 17.2143
Applicable VWAP Calculations in Accordance Shareholder Approval [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares			1,201,636
Warrant issued, shares of common stock called by warrant | shares			1,282,832
Warrants issued, exercise price | $ / shares			$ 10.7258
June Offering [Member]
Class Of Warrant Or Right [Line Items]
Issuance of placement agent warrants												$ 427,000
June Offering [Member] | June Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares	1,392,345
Stock price | $ / shares	$ 9.93
Proceeds from issuance of common stock	$ 13,800,000
Offering closing period	Jun. 14, 2018
June Private Placement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares		1,392,345
Warrants issued, exercise price | $ / shares		$ 9.94
Warrants expiration period		5 years 6 months
Proceeds from offering costs of private placement, gross		$ 174,000
Class of warrant or right number of securities called by warrants or rights, per share | $ / shares		$ 0.125

Stock-Based Compensation and _3

Stock-Based Compensation and Warrants - Additional Information (Detail)	May 20, 2015shares	May 14, 2015	Dec. 31, 2013$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Jun. 30, 2014$ / sharesshares	Sep. 30, 2018USD ($)IncentivePlan$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Number of equity incentive plans | IncentivePlan							2
Total number of options outstanding				525,194			525,194		288,129
Unrecognized compensation cost related to unvested stock-based compensation grants | $				$ 1,700,000			$ 1,700,000
Weighted-average remaining recognition period							2 years 2 months 12 days
Stock-based compensation | $							$ 998,000	$ 1,177,000
Number of warrant to purchase common stock issued				2,826,687			2,826,687
Warrants issued, exercise price | $ / shares			$ 330.40	$ 18.78			$ 18.78
June Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Number of warrant to purchase common stock issued				1,282,832			1,282,832
Warrants issued, exercise price | $ / shares				$ 10.7258			$ 10.7258
Series D Redeemable Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Warrants issued, exercise price | $ / shares						$ 363.20
Warrant, exercisable term						5 years
Warrant issued, shares of common stock called by warrant						61,397
Series D Redeemable Convertible Preferred Stock [Member] | Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Warrants issued, exercise price | $ / shares						$ 268.80
Warrant issued, shares of common stock called by warrant						1,674
Mahyco International [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Warrant issued, shares of common stock called by warrant			3,784
Warrant, exercisable term			5 years
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Total number of shares reserved for issuance under plan				89,489			89,489
Percentage in payroll deductions to acquire shares of common stock		15.00%
Purchase plan offering period		6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage		85.00%
Issuance of common stock pursuant to employee stock purchase plan							6,853
Stock-based compensation | $				$ 4,000	$ 6,000		$ 6,000	$ 11,000
Private Placement [Member] | June Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Number of warrant to purchase common stock issued				1,461,962			1,461,962
Private Placement [Member] | June Purchase Agreement [Member] | Purchase Price Of 94 [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Number of warrant to purchase common stock issued				1,392,345			1,392,345
Warrants issued, purchase price of warrants per share | $ / shares				$ 9.94			$ 9.94
Private Placement [Member] | June Purchase Agreement [Member] | Exercise Price Of 12568 [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Number of warrant to purchase common stock issued				69,617			69,617
Warrants issued, exercise price | $ / shares				$ 12.568			$ 12.568
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Warrants issued, exercise price | $ / shares				$ 8.322			$ 8.322
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Terms under the plan							The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan	154,387			484,539			484,539
Options vesting period	4 years			2 years
Common stock available for future grant				26,740			26,740
Total number of options outstanding				457,797			457,797
2015 Omnibus Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Options exercisable period	10 years
2015 Omnibus Equity Incentive Plan [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Stock options vesting percentage at end of one year	25.00%
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award and Warrants [Line Items]
Total number of shares reserved for issuance under plan	10,637
Total number of options outstanding				67,397			67,397

Stock-Based Compensation and _4

Stock-Based Compensation and Warrants - Summary of Activity Under Stock Incentive Plans (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance | shares	288,129
Shares Subject to Outstanding, Options granted | shares	287,577
Shares Subject to Outstanding, Options exercised | shares	(44,354)
Shares Subject to Outstanding, Options cancelled and forfeited | shares	(6,158)
Shares Subject to Outstanding, Ending Balance | shares	525,194
Shares Subject to Outstanding, Vested and expected to vest | shares	510,184
Shares Subject to Outstanding, Exercisable | shares	149,624
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares	$ 63.62
Weighted-Average Exercise Price Per Share, Options granted | $ / shares	6.76
Weighted-Average Exercise Price Per Share, Options exercised | $ / shares	21.73
Weighted-Average Exercise Price Per Share, Options cancelled and forfeited | $ / shares	41.54
Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares	36.34
Weighted Average Exercise Price Per Share, Vested and expected to vest | $ / shares	36.90
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 84
Aggregate Intrinsic Value, Outstanding Balance | $	$ 63
Aggregate Intrinsic Value, Vested and expected to vest | $	61
Aggregate Intrinsic Value, Exercisable | $	$ 1

Stock-Based Compensation and _5

Stock-Based Compensation and Warrants - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	5 years 6 months 7 days	6 years	5 years 11 months 19 days	6 years 1 month 13 days
Expected volatility	100.00%	80.00%	99.00%	79.00%
Risk-free interest rate	2.96%	1.94%	2.95%	1.89%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21.00%
Effective tax rate (ETR)	0.10%	(0.20%)	(0.20%)	(0.20%)
Uncertain tax positions	$ 0		$ 0

Contingent Liability Related _2

Contingent Liability Related to the Anawah Acquisition - Additional Information (Detail) $ in Thousands	Dec. 31, 2010USD ($)Program	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 3,000	$ 3,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000			$ 5,000
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs,
Number of development programs ceased | Program	3
Number of development programs | Program	6
Other noncurrent liability		$ 3,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	3,351,881	360,133
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	525,194	293,288
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	2,826,687	66,845

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Royalty fees due	$ 18	$ 29
John Sperling Revocable Trust [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 18	$ 29